Form 4: IRIDEX CEO Patrick Mercer Reports Routine Stock Disposition for Tax Obligations

IRIDEX Corp. President and CEO Patrick Mercer reported an exempt disposition of 4,243 common shares to satisfy tax withholding obligations related to restricted stock units, maintaining a beneficial ownership of 415,857 shares.

Summary

• Patrick Mercer, President and CEO of IRIDEX CORP (IRIX), reported a transaction on June 30, 2025.
• The transaction involved the disposition of 4,243 shares of Common Stock at a deemed price of $0.8819 per share.
• This disposition was an exempt transaction (Code F) where shares were withheld by the Issuer to cover income tax withholding and remittance obligations related to the net settlement of restricted stock units.
• This transaction does not represent a sale by Patrick Mercer.
• Following this transaction, Patrick Mercer beneficially owns 415,857 shares of IRIDEX CORP Common Stock directly.

Sentiment

Score: 7

Explanation: The filing reports a routine, non-discretionary transaction for tax withholding purposes related to the vesting of restricted stock units. This is a neutral event, but the underlying RSU vesting is generally positive as it represents earned compensation and aligns management interests with shareholders.

Positives

• The transaction is an exempt disposition for tax purposes, not a discretionary sale by the CEO.
• The underlying event is the net settlement of restricted stock units, indicating the vesting of equity compensation for the CEO, which aligns management interests with shareholders.

Negatives

• No direct negative implications are present as the transaction is a routine tax withholding related to equity compensation.

Future Outlook

No specific forward-looking statements or guidance are provided in this Form 4 filing, as it primarily reports a past insider transaction.

Management Comments

• Shares have been withheld in an exempt disposition to the Issuer under Rule 16b-3(e) to satisfy the Issuer's income tax withholding and remittance obligations in connection with the net settlement of restricted stock units and does not represent a sale by the Reporting Person.

Industry Context

This Form 4 filing reports a routine insider transaction related to equity compensation and tax withholding, which is common across all industries for executives receiving restricted stock units. It does not provide specific insights into broader industry trends for medical devices or ophthalmology.

Related Party Transactions

• The transaction involves the Issuer withholding shares to satisfy tax obligations related to the CEO's restricted stock units, which is a common practice for equity compensation.

Stakeholder Impact

• Shareholders: Minimal direct impact as it's a routine tax withholding, not a discretionary sale. It confirms the vesting of executive equity compensation.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Key Dates

Keywords

IRIDEX CORP, IRIX, Patrick Mercer, Form 4, SEC filing, insider transaction, stock disposition, restricted stock units, RSU, tax withholding, CEO, equity compensation